Cargando…
1577. Particle Characterization of Nebulized Liposomal Amphotericin B and Its Use in the Treatment of Murine Pulmonary Aspergillosis
BACKGROUND: Immunocompromised patients are very susceptible to pulmonary aspergillosis causing 50% mortality with present treatments, indicating a need for improved therapy. To address this, we standardized a nebulization method for effectively delivering liposomal amphotericin B (AmBisome®, AmBi) i...
Autores principales: | Dave, Janam J, Sandoval, Adilene, Olson, Jon, Adler-Moore, Jill |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809417/ http://dx.doi.org/10.1093/ofid/ofz360.1441 |
Ejemplares similares
-
1554. Nebulized Liposomal Amphotericin B for Treatment of Murine Pulmonary Mucormycosis
por: Sandoval, Adilene, et al.
Publicado: (2019) -
1639. Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole-Resistant Aspergillus fumigatus Strains
por: Olson, Jon, et al.
Publicado: (2018) -
Use of Nebulized Amphotericin B in the Treatment of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis
por: Proesmans, M., et al.
Publicado: (2010) -
Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study
por: Melchers, Max, et al.
Publicado: (2022) -
COLLABORATION AGREEMENT NO. K1577
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2008)